Japanese knotweed (Fallopia japonica) is an invasive plant species in the UK, yet it contains high concentrations of resveratrol, a polyphenolic compound with antioxidant properties. Resveratrol supplements derived from Japanese knotweed have attracted scientific interest for potential health benefits, though evidence from human clinical trials remains limited. In the UK, resveratrol is regulated as a food supplement with a maximum daily intake of 150 mg for adults. This article examines the relationship between Japanese knotweed and resveratrol, explores current research on potential health effects, and provides guidance on safe use in accordance with UK regulations and clinical standards.

What Is Japanese Knotweed and Its Link to Resveratrol?

Japanese knotweed (Fallopia japonica) is a perennial plant native to East Asia, known in the UK as an invasive species that can potentially damage buildings and infrastructure. In the UK, it is listed under Schedule 9 of the Wildlife and Countryside Act 1981, making it an offence to plant or cause it to grow in the wild.

Despite its problematic status in the UK, Japanese knotweed has a long history of use in traditional Asian medicine, where it is known as hu zhang or itadori.

The plant's medicinal interest centres on its high concentration of resveratrol, a naturally occurring polyphenolic compound classified as a stilbenoid. Resveratrol is found predominantly in the root system of Japanese knotweed, with concentrations generally higher than those found in other common dietary sources such as red grapes or peanuts. This compound functions as a phytoalexin—a defensive substance produced by plants in response to stress, infection, or injury.

Resveratrol exists in two isomeric forms: cis-resveratrol and trans-resveratrol, with the trans form being more stable and biologically active. The compound has attracted scientific attention due to its antioxidant properties and potential effects on cellular signalling pathways, particularly those involved in inflammation, metabolism, and ageing processes. Japanese knotweed extract has become a commercial source of resveratrol for dietary supplements.

It is important to note that in the UK, Japanese knotweed should not be harvested from the wild. Its disposal is controlled under waste management regulations, and any material containing it must be disposed of at licensed landfill sites. All legitimate resveratrol supplements derived from Japanese knotweed use controlled cultivation or imported raw materials that comply with UK biosecurity regulations.

Health Benefits of Resveratrol from Japanese Knotweed

Resveratrol has been studied for its potential health benefits, though it is essential to distinguish between laboratory findings and clinically proven effects in humans. Currently, there are no authorised health claims for resveratrol under the GB Nutrition and Health Claims Register, and resveratrol supplements cannot legally make claims about preventing, treating or curing diseases.

Antioxidant activity represents one of resveratrol's most well-characterised properties in laboratory studies. The compound can neutralise reactive oxygen species (free radicals) and may help protect cells from oxidative stress, a process implicated in numerous chronic diseases and ageing.

In cardiovascular health, some observational and preliminary clinical studies have suggested potential benefits. Laboratory research indicates resveratrol may influence endothelial function—the health of blood vessel linings—and has been investigated for effects on lipid profiles and blood pressure regulation. However, large-scale clinical trials demonstrating definitive cardiovascular benefits in humans remain limited, and NICE does not recommend resveratrol for cardiovascular disease prevention or treatment.

Metabolic effects have also generated research interest. Laboratory studies suggest resveratrol may influence insulin sensitivity and glucose metabolism, primarily through cellular mechanisms including sirtuin activation. Some small human trials have explored its potential role in metabolic syndrome and type 2 diabetes management, though results have been inconsistent and further research is needed.

Other areas of investigation include neuroprotection, anti-inflammatory properties, and cancer research, though these remain primarily at the preclinical or early clinical stage with limited evidence in humans.

It is crucial to emphasise that whilst these potential benefits are scientifically interesting, resveratrol supplements are not medicines and should not be used as substitutes for prescribed treatments. The evidence base from human clinical trials remains limited and often inconsistent, and the Medicines and Healthcare products Regulatory Agency (MHRA) does not authorise resveratrol products as medicinal treatments for specific conditions.

How to Use Japanese Knotweed Resveratrol Supplements Safely

Dosage considerations for resveratrol supplements vary considerably. In the UK, trans-resveratrol is authorised as a novel food ingredient with specific conditions of use. For adults, the maximum daily intake from supplements should not exceed 150 mg per day, according to the GB Authorised Novel Foods list. You should never exceed the dose stated on the product label.

When considering resveratrol supplementation, individuals should:

• Consult a healthcare professional before starting, particularly if you have existing medical conditions or take regular medications

• Choose reputable products from established manufacturers that provide clear labelling of resveratrol content and source

• Start with lower doses to assess tolerance, as higher doses may increase the risk of adverse effects

• Follow label instructions regarding timing and whether to take with food

• Maintain realistic expectations about potential benefits, recognising the distinction between preliminary research and proven clinical efficacy

• Stop taking resveratrol supplements 1-2 weeks before planned surgery due to potential effects on blood clotting

Bioavailability represents a consideration with resveratrol supplementation. The compound undergoes extensive metabolism in the liver and intestine, resulting in relatively low systemic bioavailability. Some manufacturers use different formulations or combine resveratrol with other ingredients claiming to enhance absorption, though evidence for improved clinical outcomes from these formulations remains limited.

Duration of use has not been definitively established in clinical studies. Most clinical trials have examined short to medium-term supplementation (weeks to months). Long-term safety data in humans is limited.

Pregnant or breastfeeding women should avoid resveratrol supplements due to insufficient safety data and exclusions in the novel food authorisation. Similarly, children should not take these supplements unless specifically advised by a healthcare professional, as developmental effects have not been adequately studied.

Potential Side Effects and Drug Interactions

Resveratrol supplements are generally well-tolerated at moderate doses, but adverse effects can occur, particularly at higher intakes. Commonly reported side effects include:

• Gastrointestinal symptoms: nausea, diarrhoea, abdominal discomfort, and flatulence

• Headache and dizziness: reported in some individuals

• Allergic reactions: rare but possible, particularly in individuals with sensitivities to plants in the Polygonaceae family

At higher doses, some studies have noted changes in liver enzyme levels. If you experience symptoms that might indicate liver problems (yellowing of the skin or eyes, dark urine, right upper abdominal pain, or severe fatigue), stop taking the supplement immediately and seek urgent medical advice.

Drug interactions represent an important safety consideration. Resveratrol may interact with several medication classes:

Anticoagulants and antiplatelet drugs (warfarin, direct oral anticoagulants like apixaban or rivaroxaban, clopidogrel, aspirin): Resveratrol may have antiplatelet effects that could theoretically increase bleeding risk. Patients on these medications should consult their doctor before supplementation. If taking warfarin, discuss monitoring with your anticoagulation clinic.

Cytochrome P450 substrates: Laboratory studies suggest resveratrol may inhibit certain CYP enzymes, though the clinical significance of these effects remains uncertain. Caution is advised if taking medications with a narrow therapeutic window.

Antihypertensive medications: Potential additive blood pressure-lowering effects may occur, requiring monitoring.

Patients taking any regular medications should discuss resveratrol supplementation with their GP or pharmacist before starting. It is advisable to inform all healthcare providers about supplement use, as this information is relevant for safe prescribing and monitoring.

If you experience unusual symptoms after starting resveratrol supplements, particularly if taking other medications, contact your GP promptly. For suspected adverse reactions to medicines, vaccines, medical devices or traditional herbal medicines, you can report these through the MHRA Yellow Card scheme.

UK Regulations and Quality Standards for Resveratrol Products

In the UK, resveratrol supplements derived from Japanese knotweed are regulated as food supplements rather than medicines, falling under the jurisdiction of the Food Standards Agency (FSA) and local authority trading standards. This regulatory classification means they are not subject to the same rigorous pre-market safety and efficacy testing required for licensed medicines.

Trans-resveratrol is listed on the GB Authorised Novel Foods list with specific conditions of use, including a maximum daily intake of 150 mg for adults and exclusions for use during pregnancy and lactation.

Under the Food Supplements (England) Regulations 2003 (and equivalent legislation in Scotland, Wales, and Northern Ireland), manufacturers must ensure their products are safe and accurately labelled. Importantly, there are no authorised health claims for resveratrol under the GB Nutrition and Health Claims Register, meaning products cannot legally make specific claims about preventing, treating, or curing diseases. Any such claims would reclassify the product as an unlicensed medicine, which is illegal to market.

Quality standards vary considerably among resveratrol products. When selecting a supplement, consider:

• Third-party testing: Look for products certified by independent organisations or those adhering to Good Manufacturing Practice (GMP) standards

• Clear labelling: Products should specify the amount of resveratrol per dose, the source, and any additional ingredients

• Batch testing: Reputable manufacturers conduct testing for contaminants including heavy metals, pesticides, and microbial contamination

• Traceability: Quality products should provide information about sourcing and manufacturing locations

• Business details: UK regulations require the name and address of the manufacturer or distributor on the label

The Traditional Herbal Registration (THR) scheme, overseen by the MHRA, provides a registration pathway for traditional herbal medicines with evidence of traditional use. However, most resveratrol supplements are marketed as food supplements rather than registered traditional herbal medicines.

Consumers should be cautious of products making exaggerated health claims. For suspected adverse reactions to medicines, vaccines, medical devices or traditional herbal medicines, report through the MHRA Yellow Card scheme. For food supplement quality or safety concerns, contact your local authority via the FSA 'report a food problem' service.

For evidence-based health information, the NHS website and NICE guidance remain authoritative sources. When in doubt about a product's legitimacy or safety, consult a pharmacist or GP before purchase.

Frequently Asked Questions